Literature DB >> 22968547

Miniaturized transfer models to predict the precipitation of poorly soluble weak bases upon entry into the small intestine.

Sandra Klein1, Norma L Buchanan, Charles M Buchanan.   

Abstract

For poorly soluble weak bases, the possibility of drug precipitation upon entry into the small intestine may affect the amount of drug available for uptake through the intestinal mucosa. A few years ago, a transfer model was introduced which has been developed to simulate the transfer of a dissolved drug out of the stomach into the small intestine. However, this setup requires the use of clinically relevant doses of the drug, which are typically not available in the early stages of formulation development. The present series of tests was performed to check whether it is possible to create a miniaturized but physiologically relevant transfer model that can be applied in the early formulation development. Experiments were performed with two miniaturized setups: a 96-well plate model and a mini-paddle transfer system. Itraconazole and tamoxifen were used as model drugs. An appropriate amount of each drug formulation was dissolved in simulated gastric fluid and then transferred into an acceptor phase consisting of fasted/fed state simulated small intestinal fluid. The amount of drug dissolved in the acceptor phase was monitored over a period of 4 h. Results from both setups were very similar. The tamoxifen preformulation did not precipitate, whereas the itraconazole formulation precipitated to the same extent in both setups. Due to the possibility of generating physiologically relevant results but using smaller sample sizes and smaller volumes of media, both miniaturized transfer systems offer various advantages in terms of substance and analytical and material cost savings when evaluating the precipitation potential of poorly soluble weakly basic drug candidates.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22968547      PMCID: PMC3513478          DOI: 10.1208/s12249-012-9851-y

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  9 in total

1.  Pharmaceutical profiling in drug discovery.

Authors:  Edward H Kerns; Li Di
Journal:  Drug Discov Today       Date:  2003-04-01       Impact factor: 7.851

2.  Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine.

Authors:  Edmund S Kostewicz; Martin Wunderlich; Ulrich Brauns; Robert Becker; Thomas Bock; Jennifer B Dressman
Journal:  J Pharm Pharmacol       Date:  2004-01       Impact factor: 3.765

Review 3.  The use of biorelevant dissolution media to forecast the in vivo performance of a drug.

Authors:  Sandra Klein
Journal:  AAPS J       Date:  2010-05-11       Impact factor: 4.009

Review 4.  In vitro methods to assess drug precipitation.

Authors:  Wei-Guo Dai
Journal:  Int J Pharm       Date:  2010-03-27       Impact factor: 5.875

5.  Equilibrium drug solubility measurements in 96-well plates reveal similar drug solubilities in phosphate buffer pH 6.8 and human intestinal fluid.

Authors:  Tiina Heikkilä; Milja Karjalainen; Krista Ojala; Kirsi Partola; Frank Lammert; Patrick Augustijns; Arto Urtti; Marjo Yliperttula; Leena Peltonen; Jouni Hirvonen
Journal:  Int J Pharm       Date:  2010-12-10       Impact factor: 5.875

Review 6.  Advanced screening assays to rapidly identify solubility-enhancing formulations: high-throughput, miniaturization and automation.

Authors:  Wei-Guo Dai; Crystal Pollock-Dove; Liang C Dong; Shu Li
Journal:  Adv Drug Deliv Rev       Date:  2007-11-09       Impact factor: 15.470

7.  Intraluminal pH of duodenum and jejunum in fasting subjects with normal and abnormal gastric or pancreatic function.

Authors:  A Benn; W T Cooke
Journal:  Scand J Gastroenterol       Date:  1971       Impact factor: 2.423

8.  Solubilization and dissolution of tamoxifen-hydroxybutenyl cyclodextrin complexes.

Authors:  Charles M Buchanan; Norma L Buchanan; Kevin J Edgar; Juanelle L Lambert; Jessica D Posey-Dowty; Michael G Ramsey; Michael F Wempe
Journal:  J Pharm Sci       Date:  2006-10       Impact factor: 3.534

9.  Pharmacokinetics of itraconazole after intravenous and oral dosing of itraconazole-cyclodextrin formulations.

Authors:  Charles M Buchanan; Norma L Buchanan; Kevin J Edgar; Sandra Klein; James L Little; Michael G Ramsey; Karen M Ruble; Vincent J Wacher; Michael F Wempe
Journal:  J Pharm Sci       Date:  2007-11       Impact factor: 3.534

  9 in total
  1 in total

1.  "Development of Fixed Dose Combination Products" Workshop Report: Considerations of Gastrointestinal Physiology and Overall Development Strategy.

Authors:  Bart Hens; Maura Corsetti; Marival Bermejo; Raimar Löbenberg; Pablo M González; Amitava Mitra; Divyakant Desai; Dakshina Murthy Chilukuri; Alexis Aceituno
Journal:  AAPS J       Date:  2019-06-06       Impact factor: 4.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.